Clinical trials located in

Peine

Peine city is located in Germany. Currently, 12 clinical trials are being conducted in this city.

Peine, located in Lower Saxony, Germany, is a city rich in history and culture. Established in the 13th century, it quickly became an important center for iron processing, a legacy that continues with its modern steel industry. The city is home to the historic Peine Castle, showcasing medieval architecture, and the Eixer See, a popular lake formed from a former gravel pit. Peine is also known for its annual Peiner Freischießen, a festival celebrating local traditions and community spirit, highlighting the city’s vibrant cultural life.

  • CT-EU-00057072

    Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    BelgiumDenmarkFranceGermanyNetherlandsSpainSwedenUnited Kingdom
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    BelgiumFranceGermanyGreeceHungaryItalyNetherlandsSpainUnited Kingdom
  • Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    AustriaBulgariaCzechiaGermanyGreeceHungaryNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    AlbaniaAustriaBulgariaCzechiaGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Exploring new asthma treatment for adults

    This clinical trial evaluates londamocitinib (AZD4604), a potential new treatment for adults with moderate-to-severe asthma uncontrolled by standard inhalers (ICS-LABA). Participants will receive AZD4604 or a placebo via a dry-powder inhaler over 12 weeks. The trial aims to assess the drug’s effectiveness in managing asthma symptoms and its safety. It focuses on adults whose asthma is not well-controlled by current medications, seeking to offer a new therapeutic option.

    BulgariaDenmarkFranceGermanySpainSwedenUnited Kingdom
  • Studying tozorakimab for long-term safety in patients with chronic obstructive pulmonary disease

    The research study focuses on Tozorakimab’s long-term safety and efficacy in adults over 40 with frequent COPD flare-ups. It aims to evaluate the time until the first severe flare-up post-treatment, comparing it with the effects of current COPD treatments. The study also assesses Tozorakimab’s additional benefits alongside standard care and monitors participants’ blood for drug levels and physiological reactions. This research is key in developing improved management strategies for COPD.

    BelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainSwedenUnited Kingdom
  • Benralizumab trial for Chronic Lung Disease (COPD) patients

    This Phase 3 clinical trial evaluates Benralizumab in treating COPD, a severe lung condition characterized by breathing difficulties. It specifically targets individuals who experience frequent flare-ups, despite ongoing medication. The trial requires participants to have had at least two flare-ups in the previous year and a high eosinophil count in their blood. The study involves administering Benralizumab for a minimum of 56 weeks, with the aim to assess its impact on reducing flare-ups and improving lung function.

    AustriaBelgiumBulgariaDenmarkGermanyGreeceHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Tozorakimab trial for chronic obstructive pulmonary disease (COPD) treatment

    This study is checking the effectiveness and safety of two different dose levels of a medication called tozorakimab for treating adults suffering from a long-term lung disease known as symptomatic chronic obstructive pulmonary disease (COPD). COPD patients participating in this study must have had at least two ‘moderate’ or one ‘severe’ exacerbations (flare-ups) over the last year. The study will compare how well tozorakimab works compared to an inactive substance (placebo) in delaying the time to the first exacerbation and any changes to lung function tests, such as the FEV1 test. The participants’ demonstrations of improvement based on scoring systems related to symptoms severity will also be evaluated.

    FranceGermanyGreeceItalyPolandRomaniaUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in Germany:

.